Systems Biology Opens New Research Pathways
Systems Biologists Are Attacking the Encrypted Messages That Would Allow Us to Predict and Change the Course of Disease
Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
- Karolinska Institutet Science Park
- Banvaktsvägen 22
- Solna , SE-171 48
Kancera AB is a biotechnology company that focuses on the development and sale of drug candidates that have the potential to cure or to stop the progression of cancer. Kancera is currently running two pharmaceutical development projects, one relating to solid tumors and one relating to leukemia. Through a subsidiary, Kancera also provides big pharma, mid-sized pharma and biotech companies with lead identification and optimization services such as high-throughput screening (HTS), fragment-based screening (FBS), assay development and medicinal chemistry.